Bose S, Do V, Testini C, Jadhav S, Sailliet N, Kho A
Front Transplant. 2025; 4:1518772.
PMID: 39967861
PMC: 11832486.
DOI: 10.3389/frtra.2025.1518772.
Guo R, Wang P
Breast Cancer. 2024; 32(2):227-241.
PMID: 39589625
DOI: 10.1007/s12282-024-01654-7.
Skapinker E, Aucoin E, Kombargi H, Yaish A, Li Y, Baghaie L
Cells. 2024; 13(20.
PMID: 39451257
PMC: 11506673.
DOI: 10.3390/cells13201739.
Zhang H, Felthaus O, Eigenberger A, Klein S, Prantl L
Cells. 2024; 13(18.
PMID: 39329710
PMC: 11429654.
DOI: 10.3390/cells13181526.
Zhou Z, Xu J, Liu S, Lv Y, Zhang R, Zhou X
Biomark Res. 2024; 12(1):97.
PMID: 39227959
PMC: 11373505.
DOI: 10.1186/s40364-024-00630-9.
Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.
Du G, Dou C, Sun P, Wang S, Liu J, Ma L
Front Immunol. 2024; 15:1431211.
PMID: 39136031
PMC: 11317284.
DOI: 10.3389/fimmu.2024.1431211.
Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression.
Wang Y, Li J, Nakahata S, Iha H
Int J Mol Sci. 2024; 25(13).
PMID: 39000453
PMC: 11242872.
DOI: 10.3390/ijms25137346.
Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8 T cells.
Barnkob M, Michaels Y, Andre V, Macklin P, Gileadi U, Valvo S
Nat Commun. 2024; 15(1):3173.
PMID: 38609390
PMC: 11017241.
DOI: 10.1038/s41467-024-47424-z.
FOXP3 regulatory T cell perturbation mediated by the IFNγ-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity.
Liu X, Zhang W, Han Y, Cheng H, Liu Q, Ke S
Nat Commun. 2024; 15(1):122.
PMID: 38167862
PMC: 10761945.
DOI: 10.1038/s41467-023-44391-9.
The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers.
Lin S, Chai Y, Zheng X, Xu X
Mol Biol Rep. 2023; 51(1):14.
PMID: 38085375
PMC: 10716070.
DOI: 10.1007/s11033-023-08931-2.
Neuropilin-1 identifies a subset of highly activated CD8+ T cells during parasitic and viral infections.
Abberger H, Hose M, Ninnemann A, Menne C, Eilbrecht M, Lang K
PLoS Pathog. 2023; 19(11):e1011837.
PMID: 38019895
PMC: 10718454.
DOI: 10.1371/journal.ppat.1011837.
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus.
Schnittman S, Kolossvary M, Beck-Engeser G, Fitch K, Ambayec G, Nance R
Open Forum Infect Dis. 2023; 10(10):ofad467.
PMID: 37869406
PMC: 10590105.
DOI: 10.1093/ofid/ofad467.
Overexpression of NRP1 is Associated with Poor Prognosis via Accelerating Immunosuppression in Head and Neck Squamous Cell Carcinoma.
Yang X, Xu T, Song X, Wu Y
Int J Gen Med. 2023; 16:2819-2829.
PMID: 37426519
PMC: 10329464.
DOI: 10.2147/IJGM.S409336.
CircRNA-miRNA-VEGFA: an important pathway to regulate cancer pathogenesis.
Zhang L, Zhang Y, Li X, Gao H, Chen X, Li P
Front Pharmacol. 2023; 14:1049742.
PMID: 37234708
PMC: 10206052.
DOI: 10.3389/fphar.2023.1049742.
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Nascentes Melo L, Herrera-Rios D, Hinze D, Loffek S, Oezel I, Turiello R
J Immunother Cancer. 2023; 11(4).
PMID: 37028818
PMC: 10083881.
DOI: 10.1136/jitc-2021-004150.
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.
Semeniuk-Wojtas A, Poddebniak-Strama K, Modzelewska M, Baryla M, Dziag-Dudek E, Syrylo T
Cancer Immunol Immunother. 2023; 72(7):1971-1989.
PMID: 36928373
PMC: 10264486.
DOI: 10.1007/s00262-023-03376-9.
PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort....
Chen S, Wei H, Zhao W, Jiang W, Ning R, Zhou S
Front Immunol. 2022; 13:1059995.
PMID: 36569915
PMC: 9767946.
DOI: 10.3389/fimmu.2022.1059995.
Cell-intrinsic ceramides determine T cell function during melanoma progression.
Hose M, Gunther A, Naser E, Schumacher F, Schonberger T, Falkenstein J
Elife. 2022; 11.
PMID: 36426850
PMC: 9699697.
DOI: 10.7554/eLife.83073.
Evolving therapeutic landscape of advanced hepatocellular carcinoma.
Yang C, Zhang H, Zhang L, Zhu A, Bernards R, Qin W
Nat Rev Gastroenterol Hepatol. 2022; 20(4):203-222.
PMID: 36369487
DOI: 10.1038/s41575-022-00704-9.
Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment.
Zhang H, Tomar V, Li J, Basavaraja R, Yan F, Gui J
Cancer Immunol Res. 2022; 10(12):1490-1505.
PMID: 36255418
PMC: 9722544.
DOI: 10.1158/2326-6066.CIR-22-0295.